Product Datasheet

EGLN3/PHD3 Antibody - BSA Free NB100-139

Unit Size: 0.1 ml

Store at 4C short term. Aliquot and store at -20C long term. Avoid freeze-thaw cycles.



Reviews: 2 Publications: 53

Protocols, Publications, Related Products, Reviews, Research Tools and Images at: www.novusbio.com/NB100-139

Updated 10/23/2024 v.20.1

Earn rewards for product reviews and publications.

Submit a publication at www.novusbio.com/publications Submit a review at www.novusbio.com/reviews/destination/NB100-139



NB100-139

EGLN3/PHD3 Antibody - BSA Free

Product Information	
Unit Size	0.1 ml
Concentration	1 mg/ml
Storage	Store at 4C short term. Aliquot and store at -20C long term. Avoid freeze-thaw cycles.
Clonality	Polyclonal
Preservative	0.02% Sodium Azide
Isotype	IgG
Purity	Immunogen affinity purified
Buffer	PBS
Target Molecular Weight	28 kDa
Product Description	
Host	Rabbit
Gene ID	112399
Gene Symbol	EGLN3
Species	Human, Mouse, Rat
Reactivity Notes	Mouse reactivity reported in scientific literature (PMID: 24037093)
Immunogen	Synthetic peptide corresponding to residues between 50-100 of human PHD3/HIF Prolyl Hydroxylase 3 using the numbering given in entry NP_071356.1 (GeneID 112399).
Product Application Details	
Applications	Western Blot, Chromatin Immunoprecipitation, Electron Microscopy, Immunocytochemistry/ Immunofluorescence, Immunohistochemistry, Immunohistochemistry-Paraffin, Immunoprecipitation, Knockdown Validated, Mass Spectrometry
Recommended Dilutions	Western Blot 1:1000-1:2000, Chromatin Immunoprecipitation reported in scientific literature (PMID 24367580), Immunohistochemistry 1:250-1:1000, Immunocytochemistry/ Immunofluorescence 1:500, Immunoprecipitation, Immunohistochemistry-Paraffin 1:250-1:1000, Electron Microscopy reported in scientific literature (PMID 17003483), Mass Spectrometry, Knockdown Validated
Application Notes	In WB, PHD3 band can be seen at 27-30 kDa molecular weight range. Mass Spectrometry reported in scientific literature (PMID:34426491).
Imana	

Images

Knockdown Validated: EGLN3/PHD3 Antibody [NB100-139] - PHD3 is required for SCC cell survival in prolonged hypoxia. PHD3 is induced in hypoxia. Knock-down of PHD3 expression with siRNA (siPHD3) is specific and does not affect PHD2 or HIF-1 alpha expression. siScr = scrambled control siRNA. Image collected and cropped by CiteAb from the following publication (//doi.org/10.1371/journal.pone.0014617), licensed under a CC-BY license.





Immunohistochemistry-Paraffin: EGLN3/PHD3 Antibody [NB100-139] -Analysis of a formalin fixed tissue section of human renal cell carcinoma (clear cell type) using rabbit polyclonal EGLN3/PHD3 antibody with HRP-DAB detection and hematoxylin counterstaining. The antibody generated a strong nuclear staining of PHD3 primarily in the cancer cells while the stromal cells were largely negative for this protein.



HeLa

G1

С

phase

p27

B-actin

PHD3 β-actin

siScr

siPHD3

p-p27S10

Knockdown Validated: EGLN3/PHD3 Antibody [NB100-139] -EGLN3/PHD3 depletion increases S10 phosphorylation of p27 in hypoxia. S10 phosphorylated form of p27 is strongly induced in EGLN3/PHD3 depleted cells. Image collected and cropped by CiteAb from the following publication (https://molecularcancer.biomedcentral.com/articles/10.1186/s12943-015-0410-5) licensed under a CC-BY license.

Immunocytochemistry/Immunofluorescence: EGLN3/PHD3 Antibody [NB100-139] - EGLN3/PHD3 antibody was tested in HeLa cells with Dylight 488 (green). Nuclei and alpha-tubulin were counterstained with DAPI (blue) and Dylight 550 (red).

Knockdown Validated: EGLN3/PHD3 Antibody [NB100-139] - BxPC3 cells stably transduced with retrovirus containing PHD3Wt (BxPC3-Wt), Vector (BxPC3-Vec) or anti-PHD3 shRNA (BxPC3-KD) were harvested for RNA and protein following 24 hours exposure to normoxia (21% O2) or hypoxia (1% O2). Whole cell lysate from BxPC3-Wt, BxPC3-Vec and BxPC3-KD cells following 24 hours exposure to normoxia (N) or hypoxia (H) was resolved by SDS-PAGE and blotted for actin (top) and PHD3 (bottom). PHD3 band intensity was quantified relative to actin in each lane and then normalized to BxPC3-Vec (N). Relative band intensity is indicated below the figure. NS = non-specific band running just above PHD3 band. Data is representative of >3 biological replicates. Image collected and cropped by CiteAb from the following publication (//doi.org/10.1371/journal.pone.0083021), licensed under a CC-BY license.





Western Blot: EGLN3/PHD3 Antibody [NB100-139] - The HIF-1 response A DU145 PC-3 MCF-7 MB-435 is not impaired in prostate and breast carcinoma cell lines that lack Hypoxia (hrs); 24 PHD3. Melanoma, breast and prostate cancer cell lines with methylated PHD3 promoters (MB-435, PC-3) and non-methylated promoters (MCF7, Actin DU 145) were subjected to hypoxia (1% O2) or normoxia for 24 hours. Thirty micrograms of whole cell lysate was western blotted for the PHD3 > presence of PHD3; actin was used as a loading control. Image collected and cropped by CiteAb from the following publication (//doi.org/10.1371/journal.pone.0014617), licensed under a CC-BY license. Western Blot: EGLN3/PHD3 Antibody [NB100-139] - Analysis of HeLa lysates using NB100-139. Image courtesy of Dr Gregg Semenza (The Johns Hopkins University School of Medicine, Baltimore, MD USA) α-PHD3 786-0 Cell cycle block under PHD3 depletion is accompanied by p27 induction. C a PHD3 depletion induces a cell cycle block in G0/G1. HeLa & renal cell adenocarcinoma cells (786-O) were transfected with control (siScr) or 21% O. 1%0, PHD3 targeted (siPHD3) siRNA followed by synchronization at G0 & 24siScr siScr h hypoxic exposure. Cell cycle progression was monitored by FACS siPHD1 siPHD1 analysis 8 h after cell cycle release. The combined means of three siPHD2 siPHD2 independent experiments are presented (±SEM) shown in the tables siPHD3 siPHD3 below. b PHD3 depletion induces p27 expression in HeLa cells & in 786p27 p27 O cells under hypoxia (1 % O2) & normoxia (21 % O2) by siPHD3 & independent adenoviral shRNA against PHD3. p21 or p16 expression is PHD1 PHD1 not elevated by PHD3 knockdown. c Depletion of either PHD1 or PHD2 PHD2 PHD2 by siRNA does not increase p27 expression in 786-O cells Image collected & cropped by CiteAb from the following publication β-actin **B**-actin (https://pubmed.ncbi.nlm.nih.gov/26223520), licensed under a CC-BY license. Not internally tested by Novus Biologicals. Representative picture of western blot in histopathologically unchanged tissue (N) & primary cancerous tissue (C) from patients with CRC. Immunodetection of bands was performed with Rp anti- PHD1, - PHD2, -PHD3 & - FIH Ab, followed by incubation with goat anti-rabbit HRPconjugated Ab. The membrane was stripped & incubated with Rp anti-GAPDH Ab, followed by incubation with goat anti-rabbit HRP-conjugated Ab. Bands were revealed using SuperSignal West Femto Chemiluminescent Substrate, Thermo Fisher Scientific (Rockford, IL) & Biospectrum® Imaging System 500, UVP Ltd. (Upland, CA). Image collected & cropped by CiteAb from the following publication (https://pubmed.ncbi.nlm.nih.gov/24195777), licensed under a CC-BY license. Not internally tested by Novus Biologicals.



Page 3 of 13 v.20.1 Updated 10/23/2024





Western Blot: EGLN3/PHD3 Antibody - BSA Free [NB100-139] - 5dAzaC effect on PHD3 transcript (A) & protein (B) levels in HCT116 & DLD-1 CRC cells. HCT116 & DLD-1 cells were cultured in DMEM for 6, 24 & 48 h either in the absence or in the presence of 5-dAzaC at a concentration of 1.00 or 5.00 µM under hypoxic or normoxic conditions. After incubation the cells were used for total RNA isolation & protein isolation. Total RNA was reverse-transcribed, & PHD3 cDNA levels were determined by RQ-PCR relative quantification analysis. RQ-PCR results were standardized by the geometric mean of PBGD & hMRPL19 cDNA levels. PHD3 cDNA levels are expressed as a multiplicity of the respective controls. Each sample was determined in triplicate & results are presented as the mean \pm SE from three experiments *P < 0.05. The cell protein was separated by 10% SDS-PAGE, & transferred to a membrane that was then immunoblotted with Rp anti - PHD3 Ab & incubated with goat anti-rabbit HRP-conjugated Ab. The membrane was then stripped & reblotted with Rp anti-GAPDH Ab, followed by incubation with goat anti-rabbit HRP-conjugated Ab. The band densitometry readings were normalized to GAPDH loading control. The ratio PHD3 to GAPDH for control was assumed to be 1. Image collected & cropped by CiteAb from the following publication

(https://pubmed.ncbi.nlm.nih.gov/24195777), licensed under a CC-BY license. Not internally tested by Novus Biologicals.

Western Blot: EGLN3/PHD3 Antibody - BSA Free [NB100-139] - DNA methylation & expression level of the PHD3 gene in HCT116 & DLD-1 CRC cells. A. HCT116 & DLD-1 cells were cultured under normoxic or hypoxic (1% O2) conditions for 48 hrs. Cells were then used for DNA isolation followed by bisulfite modification. Methylation percentage of three DNA fragments within the PHD3 CpG island (Additional file 1, Additional file 2) in HCT116 & DLD-1 cells under hypoxic & normoxic conditions was determined by Real Time PCR amplification of bisulfite treated standard & cell line DNA, followed by comparison of their HRM profiles. B. Cells were cultured in DMEM either in hypoxic (1%O2) or normoxic conditions for 48 hrs. After incubation, the cells were used for total RNA isolation & reverse transcription. The PHD3 cDNA levels were determined by RQ-PCR relative quantification analysis. RQ-PCR results were standardized by the geometric mean of PBGD & hMRPL19 cDNA levels. PHD3 cDNA levels are expressed as a multiplicity of these cDNA copies in the cell line's calibrator. C. Cells were cultured in DMEM either in hypoxic (1%O2) (H) or normoxic (N) conditions for 48 hrs. Cells were then used for protein isolation. Proteins were separated by 10% SDS-PAGE, & transferred to a membrane that was then immunoblotted with Rp anti - PHD3 Ab & incubated with goat anti-rabbit HRP-conjugated Ab. The membrane was then stripped & reblotted with Rp anti-GAPDH Ab, followed by incubation with goat anti-rabbit HRP-conjugated Ab. The band densitometry readings were normalized to GAPDH loading control. The ratio of PHD3 to GAPDH for DLD-1 in normoxic conditions was assumed to be 1. Image collected & cropped by CiteAb from the following publication (https://pubmed.ncbi.nlm.nih.gov/24195777), licensed under a CC-BY license. Not internally tested by Novus Biologicals.

Page 5 of 13 v.20.1 Updated 10/23/2024





Page 6 of 13 v.20.1 Updated 10/23/2024

1% O.

8

siPHD3

8

0 4





Western Blot: EGLN3/PHD3 Antibody - BSA Free [NB100-139] -Experimental setup & the effect of PHD3 silencing on 786-O proteome. a siRNA-mediated silencing of PHD3 protein level in 786-O ccRCC cell line using two individual siRNA sequences in normoxic & in hypoxic (1% O2) condition. Quantification of three biological replicates, mean \pm SEM, fold change to control (Scr). Asterisk indicates a statistically significant difference (*p < 0.05, **p < 0.01). b siRNA-mediated silencing of PHD3 mRNA expression, quantification of three individual experiments. Mean ± SEM, fold change to Scr (***p < 0.001). c Flow chart of the experimental procedure. 786-O cells were transfected with siPHD3#1 or with a nontargeting control siRNA (Scr) for 24 h followed by a hypoxic (1% O2) or normoxic (21% O2) exposure. Three independent experiments were performed; proteins were extracted, followed by in-gel digestion with trypsin. Purified peptides were ran through mass spectrometer. Protein identification was done with Mascot database search. Protein quantification was carried out with Progenesis QI, followed by testing the differential expression between sample groups using peptide-level expression change averaging (PECA). d Western blot validations of selected proteins in 786-O & RCC4 cell lines with two individual siRNA sequences targeting PHD3, representative analyses are shown Image collected & cropped by CiteAb from the following publication (http://cancerandmetabolism.biomedcentral.com/articles/10.1186/s40170 -017-0167-y), licensed under a CC-BY license. Not internally tested by Novus Biologicals.

Western Blot: EGLN3/PHD3 Antibody - BSA Free [NB100-139] - PHD3 depletion stabilizes hypoxic p27 expression by increasing p27 half-life. a Cell cycle arrest at G0 & subsequent release shows an increase of p27 expression in siPHD3 exposed cells. b Quantification for p27 expression under PHD3 depletion at indicated time points after cell cycle release in HeLa & 786-O cells. Asterisk indicates significant difference (p < 0.05; n = 3). c Cell cycle arrest at G0 & inhibition of protein synthesis with cycloheximide indicate increased p27 stability in PHD3 depleted HeLa cells. d Quantification of p27 expression using siPHD3 or control at indicated time points. Four independent experiments (± SEM) are shown (p < 0.05; n = 4). e Analysis of p27 stability in 786–0 cells by cycloheximide chase during reoxygenation after 24 h hypoxia demonstrates markedly increased half-life of p27 upon PHD3 depletion Image collected & cropped by CiteAb from the following publication (https://pubmed.ncbi.nlm.nih.gov/26223520), licensed under a CC-BY license. Not internally tested by Novus Biologicals.

Page 7 of 13 v.20.1 Updated 10/23/2024





Western Blot: EGLN3/PHD3 Antibody - BSA Free [NB100-139] - PHD3 inhibition reduces the amount of hyperphosphorylated Rb & increases p27 in hypoxia.(A) SCC2 cells were transfected with the indicated siRNAs & exposed to normoxia or hypoxia for 24 to 48 hours followed by western blot analysis of PHD3, phosphorylated Rb (p-Rb) & cyclin B1. (B) HeLa cells were transfected with the indicated siRNAs, synchronized & exposed to normoxia or hypoxia for 6 to 24 hours after release. PHD3, phosphorylated Rb (p-Rb) & cyclin D1 were analyzed from samples by western blotting. (C) SCC2 cells were transfected with the indicated siRNAs & exposed to normoxia or hypoxia for 24 hours followed by western blot analysis of p21(Cip1). (D) Cells transfected with the indicated siRNAs & exposed to normoxia or hypoxia for 24 hours followed by western blot analysis of p16 & p27. Hypoxia was monitored by HIF-1a expression. (E) Cells transfected with the indicated siRNAs & exposed to normoxia or hypoxia for 24 & 48 hours followed by western blot analysis of p27. Image collected & cropped by CiteAb from the following publication (https://pubmed.ncbi.nlm.nih.gov/22087251), licensed under a CC-BY license. Not internally tested by Novus Biologicals.

Western Blot: EGLN3/PHD3 Antibody - BSA Free [NB100-139] - Cell cycle block under PHD3 depletion is accompanied by p27 induction. a PHD3 depletion induces a cell cycle block in G0/G1. HeLa & renal cell adenocarcinoma cells (786-O) were transfected with control (siScr) or PHD3 targeted (siPHD3) siRNA followed by synchronization at G0 & 24h hypoxic exposure. Cell cycle progression was monitored by FACS analysis 8 h after cell cycle release. The combined means of three independent experiments are presented (±SEM) shown in the tables below. b PHD3 depletion induces p27 expression in HeLa cells & in 786-O cells under hypoxia (1 % O2) & normoxia (21 % O2) by siPHD3 & independent adenoviral shRNA against PHD3. p21 or p16 expression is not elevated by PHD3 knockdown. c Depletion of either PHD1 or PHD2 by siRNA does not increase p27 expression in 786-O cells Image collected & cropped by CiteAb from the following publication (https://pubmed.ncbi.nlm.nih.gov/26223520), licensed under a CC-BY license. Not internally tested by Novus Biologicals.

Western Blot: EGLN3/PHD3 Antibody - BSA Free [NB100-139] - p27S10 phosphorylation is required for PHD3 depletion induced increase in p27 half-life. a Quantification of p27S10 phosphorylation from three independent experiments in 786-O cells. S10 phosphorylation demonstrated 2-fold increase at 6 h after cell cycle release in PHD3 depleted cells. b Serum starved 786-O cells were released from G0 block & S10 phosphorylation was monitored at the indicated timepoints under PHD3 depletion. PHD3 depletion had a prominent effect on S10 phosphorylation of p27. c Verification of subcellular localization of p27 plasmids. Immunofluorescence staining of Flag-p27wt / Flag-p27S10A transfected HeLa cells after 24 h hypoxia. As expected, p27wt is localized more into cytoplasmic than nuclear compartment. p27S10A is more localized into nucleus than into cytoplasm. Quantification of the subcellular localization from three optical fields (40x) (N; nuclear, C; cytoplasmic). d Flag-p27wt & S10A phosphorylation-deficient mutant (p27S10A) were transfected into siRNA-exposed HeLa cells. After 24 h of hypoxia CHX chase was performed. p27wt demonstrates strongly increased stability in siPHD3 exposed cells whereas p27S10A did not show any increased stability Image collected & cropped by CiteAb from the following publication (https://pubmed.ncbi.nlm.nih.gov/26223520), licensed under a CC-BY license. Not internally tested by Novus Biologicals.





Western Blot: EGLN3/PHD3 Antibody - BSA Free [NB100-139] - PHD3 depletion stabilizes hypoxic p27 expression by increasing p27 half-life. a Cell cycle arrest at G0 & subsequent release shows an increase of p27 expression in siPHD3 exposed cells. b Quantification for p27 expression under PHD3 depletion at indicated time points after cell cycle release in HeLa & 786-O cells. Asterisk indicates significant difference (p < 0.05; n = 3). c Cell cycle arrest at G0 & inhibition of protein synthesis with cycloheximide indicate increased p27 stability in PHD3 depleted HeLa cells. d Quantification of p27 expression using siPHD3 or control at indicated time points. Four independent experiments (± SEM) are shown (p < 0.05; n = 4). e Analysis of p27 stability in 786–0 cells by cycloheximide chase during reoxygenation after 24 h hypoxia demonstrates markedly increased half-life of p27 upon PHD3 depletion Image collected & cropped by CiteAb from the following publication (https://pubmed.ncbi.nlm.nih.gov/26223520), licensed under a CC-BY license. Not internally tested by Novus Biologicals.

Western Blot: EGLN3/PHD3 Antibody - BSA Free [NB100-139] - Hypoxia induced dedifferentiation employs both HIF-dependent & independent mechanismsA. Mammosphere formation efficiency in MCF-7 cells transfected with siHIF1a and/or siHIF2a, & cultured in normoxia or hypoxia for 3 days. B. Percentage of ALDH+ cells in T47D cells transfected with siHIF1a and/or siHIF2a, & cultured in normoxia or hypoxia. C. Percentage of CD44+CD24-/low cells from MDA-MB-468 cells transfected with siHIF1a and/or siHIF2a, & cultured in normoxia or hypoxia. Data are presented as mean ±SEM of 8 independent experiments. (D, E) HIF1a & HIF2a mRNA D. & protein E. expression in CSCs & non-CSCs from MDA-MB-468 cells cultured in normoxia or hypoxia. F. Percentage of CD44+CD24-/low MDA-MB-468 cells grown in normoxia after silencing all three PHDs individually or collectively or in hypoxia. G. Protein expression of HIF1a & HIF2a in MDA-MB-468 cells transfected with a control siRNA or a siRNA directed to PHD3 & cultured in normoxia or hypoxia. H., I. PHD1, PHD2 & PHD3 mRNA H. & protein I. expression levels in CSCs & non-CSCs sorted from MDA-MB-468 cells. B, D, F & H show means ±SD of three independent experiments. Image collected & cropped by CiteAb from the following publication (https://www.oncotarget.com/lookup/doi/10.18632/oncotarget.5564), licensed under a CC-BY license. Not internally tested by Novus Biologicals.





Publications

Lassi Luomala, Kalle Mattila, Paula Vainio, Harry Nisén, Teijo Pellinen, Jouni Lohi, Teemu D. Laajala, Petrus Järvinen, Anna Riina Koskenniemi, Panu Jaakkola, Tuomas Mirtti Low nuclear expression of HIF hydroxylases PHD2 / EGLN1 and PHD3 / EGLN3 are associated with poor recurrence free survival in clear cell renal cell carcinoma Cancer Medicine 2024-02-24 [PMID: 38400673]

Zhang L, Peng S, Dai X et al. Tumor suppressor SPOP ubiquitinates and degrades EgIN2 to compromise growth of prostate cancer cells Cancer Lett 2017-01-13 [PMID: 28089830]

Zhang, T;Xu, D;Liu, J;Wang, M;Duan, LJ;Liu, M;Meng, H;Zhuang, Y;Wang, H;Wang, Y;Lv, M;Zhang, Z;Hu, J;Shi, L;Guo, R;Xie, X;Liu, H;Erickson, E;Wang, Y;Yu, W;Dang, F;Guan, D;Jiang, C;Dai, X;Inuzuka, H;Yan, P;Wang, J;Babuta, M;Lian, G;Tu, Z;Miao, J;Szabo, G;Fong, GH;Karnoub, AE;Lee, YR;Pan, L;Kaelin, WG;Yuan, J;Wei, W; Prolonged hypoxia alleviates prolyl hydroxylation-mediated suppression of RIPK1 to promote necroptosis and inflammation Nature cell biology 2023-07-03 [PMID: 37400498]

Chen Y, Liu Y, Xiong J et al. LINC02774 inhibits glycolysis in glioma to destabilize HIF-1? dependent on transcription factor RP58 MedComm (2020) 2023-09-11 [PMID: 37701531]

Seike K, Kiledal A, Fujiwara H et al. Ambient oxygen levels regulate intestinal dysbiosis and GVHD severity after allogeneic stem cell transplantation Immunity 2023-02-01 [PMID: 36736321] (WB, Mouse)

Details:

Dilution used 1:1000

Saggese P, Pandey A, Fung E et al. Glucose deprivation promotes pseudo-hypoxia and de-differentiation in lung adenocarcinoma bioRxiv : the preprint server for biology 2023-02-01 [PMID: 36778362] (WB, Human)

Details:

Dilution used in WB 1:500

Yoon, H, Spinelli, J B Et al. PHD3 Loss Promotes Exercise Capacity and Fat Oxidation in Skeletal Muscle. Cell Metab 2020-08-04 [PMID: 32663458] (WB, Human)

Ciminera AK, Shuck SC, Termini J Elevated glucose increases genomic instability by inhibiting nucleotide excision repair Life science alliance 2021-10-01 [PMID: 34426491] (MS, Human)

Nasteska D, Cuozzo F, Viloria K Et Al. Prolyl-4-hydroxylase 3 maintains beta-cell glucose metabolism during fatty acid excess in mice JCI insight 2021-07-15 [PMID: 34264866] (IHC-P)

Ju S, Lim L, Wi K et al. LRP5 Regulates HIF-1 alpha Stability via Interaction with PHD2 in Ischemic Myocardium International Journal of Molecular Sciences 2021-06-19 [PMID: 34205318] (IP, Rat)

Kozlova N, Mennerich D, Samoylenko A et al. The pro-oncogenic adaptor CIN85 inhibits hypoxia-inducible factor prolyl hydroxylase-2. Cancer Res 2019-05-31 [PMID: 31142511] (WB, Human)

Shi M, Dai WQ, Jia RR et al. APCCDC20-mediated degradation of PHD3 stabilizes HIF-1a and promotes tumorigenesis in hepatocellular carcinoma Cancer Lett 2020-10-09 [PMID: 33039559] (WB, IP, Mouse)

More publications at http://www.novusbio.com/NB100-139



Procedures

Immunohistochemistry-Paraffin Protocol for EGLN3/PHD3 Antibody (NB100-139)

Immunohistochemistry-Paraffin Embedded Sections

Antigen Unmasking:

Bring slides to a boil in 10 mM sodium citrate buffer (pH 6.0) then maintain at a sub-boiling temperature for 10 minutes. Cool slides on bench-top for 30 minutes (keep slides in the sodium citrate buffer at all times).

Staining:

- 1. Wash sections in deionized water three times for 5 minutes each.
- 2. Wash sections in PBS for 5 minutes.
- 3. Block each section with 100-400 ul blocking solution (1% BSA in PBS) for 1 hour at room temperature.
- 4. Remove blocking solution and add 100-400 ul diluted primary antibody. Incubate overnight at 4 C.
- 5. Remove antibody solution and wash sections in wash buffer three times for 5 minutes each.
- 6. Add 100-400 ul HRP polymer conjugated secondary antibody. Incubate 30 minutes at room temperature.
- 7. Wash sections three times in wash buffer for 5 minutes each.
- 8. Add 100-400 ul DAB substrate to each section and monitor staining closely.
- 9. As soon as the sections develop, immerse slides in deionized water.
- 10. Counterstain sections in hematoxylin.
- 11. Wash sections in deionized water two times for 5 minutes each.
- 12. Dehydrate sections.
- 13. Mount coverslips.

Immunocytochemistry/ Immunofluorescence Protocol for EGLN3/PHD3 Antibody (NB100-139) Immunocytochemistry Protocol

Culture cells to appropriate density in 35 mm culture dishes or 6-well plates.

1. Remove culture medium and wash the cells briefly in PBS. Add 10% formalin to the dish and fix at room temperature for 10 minutes.

- 2. Remove the formalin and wash the cells in PBS.
- 3. Permeablize the cells with 0.1% Triton X100 or other suitable detergent for 10 min.

4. Remove the permeablization buffer and wash three times for 10 minutes each in PBS. Be sure to not let the specimen dry out.

5. To block nonspecific antibody binding, incubate in 10% normal goat serum from 1 hour to overnight at room temperature.

6. Add primary antibody at appropriate dilution and incubate overnight at 4C.

- 7. Remove primary antibody and replace with PBS. Wash three times for 10 minutes each.
- 8. Add secondary antibody at appropriate dilution. Incubate for 1 hour at room temperature.
- 9. Remove secondary antibody and replace with PBS. Wash three times for 10 minutes each.

10. Counter stain DNA with DAPi if required.



Western Blot Protocol for EGLN3/PHD3 Antibody (NB100-139)

Western Blot Protocol

1. Perform SDS-PAGE on samples to be analyzed, loading 10-25 ug of total protein per lane.

2. Transfer proteins to PVDF membrane according to the instructions provided by the manufacturer of the membrane and transfer apparatus.

3. Stain the membrane with Ponceau S (or similar product) to assess transfer success, and mark molecular weight standards where appropriate.

4. Rinse the blot TBS -0.05% Tween 20 (TBST).

5. Block the membrane in 5% Non-fat milk in TBST (blocking buffer) for at least 1 hour.

6. Wash the membrane in TBST three times for 10 minutes each.

7. Dilute primary antibody in blocking buffer and incubate overnight at 4C with gentle rocking.

8. Wash the membrane in TBST three times for 10 minutes each.

9. Incubate the membrane in diluted HRP conjugated secondary antibody in blocking buffer (as per manufacturer's instructions) for 1 hour at room temperature.

10. Wash the blot in TBST three times for 10 minutes each (this step can be repeated as required to reduce background).

11. Apply the detection reagent of choice in accordance with the manufacturer's instructions.





Novus Biologicals USA

10730 E. Briarwood Avenue Centennial, CO 80112 USA Phone: 303.730.1950 Toll Free: 1.888.506.6887 Fax: 303.730.1966 nb-customerservice@bio-techne.com

Bio-Techne Canada

21 Canmotor Ave Toronto, ON M8Z 4E6 Canada Phone: 905.827.6400 Toll Free: 855.668.8722 Fax: 905.827.6402 canada.inquires@bio-techne.com

Bio-Techne Ltd

19 Barton Lane Abingdon Science Park Abingdon, OX14 3NB, United Kingdom Phone: (44) (0) 1235 529449 Free Phone: 0800 37 34 15 Fax: (44) (0) 1235 533420 info.EMEA@bio-techne.com

General Contact Information

www.novusbio.com Technical Support: nb-technical@biotechne.com Orders: nb-customerservice@bio-techne.com General: novus@novusbio.com

Products Related to NB100-139

NBP2-24891	Rabbit IgG Isotype Control
NB7160	Goat anti-Rabbit IgG (H+L) Secondary Antibody [HRP]
HAF008	Goat anti-Rabbit IgG Secondary Antibody [HRP]
NBL1-10156	EGLN3/PHD3 Overexpression Lysate

Limitations

This product is for research use only and is not approved for use in humans or in clinical diagnosis. Primary Antibodies are guaranteed for 1 year from date of receipt.

For more information on our 100% guarantee, please visit www.novusbio.com/guarantee

Earn gift cards/discounts by submitting a review: www.novusbio.com/reviews/submit/NB100-139

Earn gift cards/discounts by submitting a publication using this product: www.novusbio.com/publications

www.novusbio.com

